Oct 7, 2024, 10:00 PM
Oct 7, 2024, 10:00 PM

Sciwind Biosciences presents GLP-2 research at UEG Week 2024 in Vienna

Highlights
  • The 32nd United European Gastroenterology Week will be held in Vienna, Austria, from October 12 to 15, 2024.
  • Sciwind Biosciences will present research on an oral formulation of GLP-2 for treating short bowel syndrome, a condition that severely impacts nutrient absorption.
  • The development of this oral treatment could enhance patient compliance and convenience compared to current injectable options.
Story

In Vienna, Austria, from October 12 to 15, 2024, the 32nd United European Gastroenterology Week will convene, marking a significant event in the gastroenterology field. This conference is recognized as the largest in Europe, attracting experts, researchers, and industry representatives to discuss advancements in clinical practices and treatment solutions. Sciwind Biosciences Co., Ltd. is set to present its latest research on an innovative oral formulation of glucagon-like peptide 2 (GLP-2), aimed at treating short bowel syndrome. This condition, characterized by malabsorption due to reduced small intestine length, poses serious health challenges, including malnutrition and chronic diarrhea. Currently, injectable GLP-2 analogs are available, but the development of an oral, long-acting version could significantly enhance patient compliance and convenience. The presentation will be led by Dr. Haixia Zou, focusing on the potential of this new treatment to improve the quality of life for patients suffering from this debilitating syndrome.

Opinions

You've reached the end